OrbiMed

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

InspireMD, Inc. is a medical device company based in Tel Aviv, Israel, specializing in the development and commercialization of its proprietary MicroNet stent platform technology aimed at treating vascular and coronary diseases. The company offers two primary products: the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection system, used in patients with acute coronary syndromes and saphenous vein graft interventions. InspireMD is also working on the NGuard neurovascular flow diverter, which aims to divert blood flow from cerebral aneurysms to enhance patient outcomes. The company's products are marketed through local distributors in various regions, including Europe, Latin America, the Middle East, and Asia.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

GentiBio, Inc. is a biotherapeutics company that specializes in developing engineered regulatory T cells, known as EngTregs, aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, Washington, GentiBio employs a proprietary platform that combines autologous and allogeneic technologies. This platform enhances the ability to restore immune tolerance and addresses significant limitations found in existing regulatory T-cell therapeutics. By focusing on the underlying mechanisms of immune system disorders, GentiBio aims to provide innovative therapeutic solutions that tackle the root causes of diseases caused by dysregulated immune responses. The company is co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of advanced immunotherapy development.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

MobileODT develops optical diagnostic devices and software for early cancer detection, enabling health care providers to perform visual examinations with portable, internet-connected tools. The Enhanced Visual Assessment system includes the FDA-cleared EVA COLPO portable colposcope and accompanying software to securely store and manage patient data via HIPAA-compliant cloud services such as EVA SANE, and a digital visualization tool for gynecologic exams, EVA WELL. The company also offers a portfolio of aids for screening, including a mobile app for Android that enables remote image capture and patient information tracking, an online portal for collaboration and reporting, and cloud storage solutions for documented patient data. Founded in 2012 and based in Tel Aviv with an additional location in New York, MobileODT aims to extend expert-level diagnostic capabilities to diverse healthcare settings and geographies, including applications in cervical cancer screening and other visual-based diagnostics.

GentiBio, Inc. is a biotherapeutics company that specializes in developing engineered regulatory T cells, known as EngTregs, aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, Washington, GentiBio employs a proprietary platform that combines autologous and allogeneic technologies. This platform enhances the ability to restore immune tolerance and addresses significant limitations found in existing regulatory T-cell therapeutics. By focusing on the underlying mechanisms of immune system disorders, GentiBio aims to provide innovative therapeutic solutions that tackle the root causes of diseases caused by dysregulated immune responses. The company is co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of advanced immunotherapy development.

TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases. Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusive technology lowers the extra BCAA that is floating around.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

Founded in 2003, Atox Bio is a biotechnology company specializing in immunomodulators for treating critically ill patients with severe infections. Its focus lies in developing novel modulators targeting key pathways of the adaptive and innate immune response to improve outcomes in critical care settings.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

RDD Pharma, Ltd. is a pharmaceutical company based in Tel-Aviv, Israel, with an additional office in New York, New York. Founded in 2008, RDD Pharma focuses on the development and commercialization of targeted therapeutics for anorectal diseases and gastrointestinal disorders. The company specializes in creating innovative pharmacological treatments for conditions such as chronic anal fissures, fecal incontinence, and pruritus ani, particularly in patients with spinal cord injuries. RDD Pharma addresses the unique challenges of treating these conditions by employing specialized formulation and delivery techniques that cater to the anatomical and physiological variations in this sensitive area.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

MobileODT develops optical diagnostic devices and software for early cancer detection, enabling health care providers to perform visual examinations with portable, internet-connected tools. The Enhanced Visual Assessment system includes the FDA-cleared EVA COLPO portable colposcope and accompanying software to securely store and manage patient data via HIPAA-compliant cloud services such as EVA SANE, and a digital visualization tool for gynecologic exams, EVA WELL. The company also offers a portfolio of aids for screening, including a mobile app for Android that enables remote image capture and patient information tracking, an online portal for collaboration and reporting, and cloud storage solutions for documented patient data. Founded in 2012 and based in Tel Aviv with an additional location in New York, MobileODT aims to extend expert-level diagnostic capabilities to diverse healthcare settings and geographies, including applications in cervical cancer screening and other visual-based diagnostics.

Mitoconix Bio Ltd is a biotechnology company established in 2016 and headquartered in Jerusalem, Israel, focused on developing innovative therapies aimed at enhancing mitochondrial health to treat neurodegenerative diseases. The company employs a disease-modifying approach that targets the functions of mitochondria, which are essential for generating ATP, regulating calcium, and maintaining cellular balance. Mitochondria play a crucial role in neuron function, undergoing constant changes in structure through processes known as fission and fusion. Disruptions in these processes can lead to reduced energy production and increased oxidative stress, contributing to cellular dysfunction and death. Mitoconix's lead drug is a first-in-class inhibitor designed to counteract pathological mitochondrial fragmentation and has shown promising efficacy in preclinical models of Huntington's disease and Parkinson's disease, as well as beneficial effects in patient-derived cells associated with these conditions and Alzheimer's disease.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic product candidates. Based in San Ramon, California, with a research and development center in Rehovot, Israel, the company offers a unique delivery platform known as PatchPump, which is a customizable, pre-filled, and pre-programmed disposable device designed for large volume and viscous formulations. Among its key products is Trevyent, a single-use PatchPump pre-filled with treprostinil for the treatment of pulmonary arterial hypertension. SteadyMed also develops SMT-201 for the subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug, and SMT-301 to deliver bupivacaine directly into surgical wound areas for localized pain relief. The company's innovative approach aims to enhance the delivery of injectable therapeutic drugs, addressing various medical needs such as pain management and chronic conditions.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic product candidates. Based in San Ramon, California, with a research and development center in Rehovot, Israel, the company offers a unique delivery platform known as PatchPump, which is a customizable, pre-filled, and pre-programmed disposable device designed for large volume and viscous formulations. Among its key products is Trevyent, a single-use PatchPump pre-filled with treprostinil for the treatment of pulmonary arterial hypertension. SteadyMed also develops SMT-201 for the subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug, and SMT-301 to deliver bupivacaine directly into surgical wound areas for localized pain relief. The company's innovative approach aims to enhance the delivery of injectable therapeutic drugs, addressing various medical needs such as pain management and chronic conditions.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

Founded in 2003, Atox Bio is a biotechnology company specializing in immunomodulators for treating critically ill patients with severe infections. Its focus lies in developing novel modulators targeting key pathways of the adaptive and innate immune response to improve outcomes in critical care settings.

Medigus is a medical device company that develops, produces, and markets minimally invasive endoscopic tools and direct visualization technology worldwide. Founded in 1999 and headquartered in Omer, Israel, it offers the Ultrasonic Surgical Endostapler and a complete endoscopic system for intraluminal treatment of gastroesophageal reflux disease. The system combines a miniature video camera, a surgical stapler, and ultrasonic alignment to enable a true partial anterior fundoplication without open or laparoscopic surgery. Medigus also designs and manufactures endoscopy systems for partners, providing the world’s smallest video cameras, processors, and a range of disposable endoscopes. The company focuses on innovative endoscopic procedures and aims to shift GERD treatment from surgery to endoluminal procedures.

TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company headquartered in Tel Aviv, Israel, with a primary focus on gastrointestinal and infectious diseases. The company develops and promotes several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for treating Helicobacter pylori infection, and Aemcolo for travelers' diarrhea. RedHill's late-stage clinical development programs include RHB-204, aimed at treating pulmonary nontuberculous mycobacteria infections; RHB-104 for Crohn's disease; and RHB-102 (Bekinda), which has shown promise in Phase 3 studies for acute gastroenteritis and gastritis. Additionally, the company is advancing RHB-107, a serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and opaganib, which is being investigated for various conditions, including COVID-19. Founded in 2009, RedHill Biopharma is committed to innovation in the management of gastrointestinal and infectious diseases.

Founded in 2008, Treato Ltd. operates Treato, a platform that aggregates and analyzes patient experiences from online health discussions. It provides insights for patients, healthcare professionals, pharmaceutical companies, and other organizations to understand patient needs and attitudes.

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. Its development pipeline includes motixafortide (BL-8040) for stem cell mobilization and solid tumors, AGI-134 for solid tumors, and BL-5010, a legacy product for the non-surgical removal of skin lesions. The company collaborates with major partners to evaluate combinations in cancer therapies, including MSD, a study with MD Anderson Cancer Center combining motixafortide with pembrolizumab in pancreatic cancer, and a Genentech collaboration to test motixafortide with atezolizumab in solid tumors. Headquartered in Israel, BioLineRx aims to advance its programs through clinical development and strategic alliances.

cCAM Biotherapeutics Ltd. is a clinical-stage biotechnology company based in Misgav, Israel, focused on the discovery and development of innovative immunotherapies for cancer treatment. The company is developing CM-10, an immunomodulatory antibody designed to enhance the immune system's ability to target and attack tumors by binding to CEACAM1, a protein that cancer cells exploit to evade immune responses. cCAM's lead therapeutic candidate, CM-24, is a humanized anti-CEACAM1 monoclonal antibody aimed at treating advanced and recurrent cancers, including melanoma, non-small-cell lung cancer, bladder, gastric, colorectal, and ovarian cancers. Established in 2010, cCAM Biotherapeutics aims to provide effective treatment options for patients facing various malignancies.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

SMT is a Herzliya Pituach, Israel-based medical device company founded in 2004. SMT is focused on the development and commercialization of procedural tools and accessories for use during TAVI and other complex percutaneous structural heart procedures.